文献速递临床试验与 GCP流行病学与生物统计

维生素D与ω-3脂肪酸补充对2型糖尿病患者肾功能的影响:一项随机临床试验

Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

这项2×2析因随机临床试验纳入1312例2型糖尿病成人,随机接受维生素D3(2000 IU/d)和/或ω-3脂肪酸(1 g/d)或安慰剂治疗5年。主要结局为基线至第5年估算肾小球滤过率(eGFR)的变化。结果显示,与安慰剂相比,维生素D3或ω-3脂肪酸补充对eGFR变化均无显著差异,研究结论不支持使用维生素D或ω-3脂肪酸补充来保护2型糖尿病患者的肾功能。

要点

  • 在2型糖尿病成人中,维生素D3或ω-3脂肪酸补充5年,eGFR变化与安慰剂相比无显著差异。
  • 维生素D3组与安慰剂组eGFR差值0.9 mL/min/1.73 m²(95%CI -0.7至2.5),未达统计学显著。
  • ω-3脂肪酸组与安慰剂组eGFR差值0.9 mL/min/1.73 m²(95%CI -0.7至2.6),未达统计学显著。

核心结论

  • 在2型糖尿病成人中,与安慰剂相比,补充维生素D3或ω-3脂肪酸5年对eGFR变化无显著差异。
  • 研究结果不支持使用维生素D或ω-3脂肪酸补充来保护2型糖尿病患者的肾功能。

研究设计与样本

  • 随机临床试验,采用2×2析因设计,作为VITAL研究的辅助研究。
  • 2011年11月至2014年3月从美国全部50个州招募1312例2型糖尿病成人,由马萨诸塞州单一中心协调。
  • 随访于2017年12月完成。
  • 参与者随机接受维生素D3(2000 IU/d)和ω-3脂肪酸(二十碳五烯酸和二十二碳六烯酸;1 g/d)(n=370)、维生素D3和安慰剂(n=333)、安慰剂和ω-3脂肪酸(n=289)或双安慰剂(n=320),为期5年。
  • 主要结局为基线至第5年基于血清肌酐和胱抑素C估算的肾小球滤过率(eGFR)的变化。

主要发现

  • 1312例随机参与者平均年龄67.6岁,46%为女性,31%为种族或族裔少数群体,934例(71%)完成研究。
  • 基线平均eGFR为85.8(SD 22.1)mL/min/1.73 m²。
  • 基线至第5年eGFR平均变化:维生素D3组-12.3(95%CI -13.4至-11.2)mL/min/1.73 m² vs 安慰剂组-13.1(95%CI -14.2至-11.9)mL/min/1.73 m²,差值0.9(95%CI -0.7至2.5)mL/min/1.73 m²。
  • 基线至第5年eGFR平均变化:ω-3脂肪酸组-12.2(95%CI -13.3至-11.1)mL/min/1.73 m² vs 安慰剂组-13.1(95%CI -14.2至-12.0)mL/min/1.73 m²,差值0.9(95%CI -0.7至2.6)mL/min/1.73 m²。
  • 两种干预之间无显著交互作用。

临床怎么用

  • 研究结论不支持使用维生素D或ω-3脂肪酸补充来保护2型糖尿病患者的肾功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chronic kidney disease (CKD) is a common complication of type 2 diabetes that can lead to end-stage kidney disease and is associated with high cardiovascular risk. Few treatments are available to prevent CKD in type 2 diabetes. OBJECTIVE: To test whether supplementation with vitamin D3 or omega-3 fatty acids prevents development or progression of CKD in type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial with a 2 × 2 factorial design conducted among 1312 adults with type 2 diabetes recruited between November 2011 and March 2014 from all 50 US states as an ancillary study to the Vitamin D and Omega-3 Trial (VITAL), coordinated by a single center in Massachusetts. Follow-up was completed in December 2017. INTERVENTIONS: Participants were randomized to receive vitamin D3 (2000 IU/d) and omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid; 1 g/d) (n = 370), vitamin D3 and placebo (n = 333), placebo and omega-3 fatty acids (n = 289), or 2 placebos (n = 320) for 5 years. MAIN OUTCOMES AND MEASURES: The primary outcome was change in glomerular filtration rate estimated from serum creatinine and cystatin C (eGFR) from baseline to year 5. RESULTS: Among 1312 participants randomized (mean age, 67.6 years; 46% women; 31% of racial or ethnic minority), 934 (71%) completed the study. Baseline mean eGFR was 85.8 (SD, 22.1) mL/min/1.73 m2. Mean change in eGFR from baseline to year 5 was -12.3 (95% CI, -13.4 to -11.2) mL/min/1.73 m2 with vitamin D3 vs -13.1 (95% CI, -14.2 to -11.9) mL/min/1.73 m2 with placebo (difference, 0.9 [95% CI, -0.7 to 2.5] mL/min/1.73 m2). Mean change in eGFR was -12.2 (95% CI, -13.3 to -11.1) mL/min/1.73 m2 with omega-3 fatty acids vs -13.1 (95% CI, -14.2 to -12.0) mL/min/1.73 m2 with placebo (difference, 0.9 [95% CI, -0.7 to 2.6] mL/min/1.73 m2). There was no significant interaction between the 2 interventions. Kidney stones occurred among 58 participants (n = 32 receiving vitamin D3 and n = 26 receiving placebo) and gastrointestinal bleeding among 45 (n = 28 receiving omega-3 fatty acids and n = 17 receiving placebo). CONCLUSIONS AND RELEVANCE: Among adults with type 2 diabetes, supplementation with vitamin D3 or omega-3 fatty acids, compared with placebo, resulted in no significant difference in change in eGFR at 5 years. The findings do not support the use of vitamin D or omega-3 fatty acid supplementation for preserving kidney function in patients with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01684722.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. de Boer IH, Zelnick LR, Ruzinski J, et al. Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2019. PMID: 31703120. doi:10.1001/jama.2019.17380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。